title: Oral beta2-agonist use by preschool children with asthma in East and Central Harlem, New York.
abstract: Although studies have documented underuse of controller medications and overuse of short-acting inhaled ss(2)-agonist among children with persistent asthma in disadvantaged communities, the persistence of oral ss(2)-agonist use in pediatric practice has not been studied since inhaled short-acting ss(2)-agonists became widespread. We describe medications used to treat asthma among children 3 to 5 years of age at 10 Head Start and other subsidized preschool centers in East and Central Harlem, New York City. We interviewed 149 parents/guardians of children who were identified as having probable asthma based on physician's diagnosis, persistent symptoms, hospitalization, and medication use. We classified 86 of the 149 children (58%) as having current persistent asthma. Only 15 of them (17%) were reported to have used controller medications at least 5 days/week in the last 4 weeks-only 2 of whom used inhaled corticosteroids. By contrast, 53 children (62%) used oral ss(2)-agonist in the last 4 weeks, often (72%) in conjunction with nebulized or inhaled short-acting ss(2)-agonist. Use of oral ss(2)-agonist was associated with more severe symptoms. This study documents the continued widespread use of oral ss(2)-agonist for treatment of children in a low-income community with high prevalence of asthma.
authors.affiliation: Center for Urban Epidemiologic Studies, The New York Academy of Medicine, New York, NY 10029-5293
authors.forename: Sebastian
authors.initials: S
authors.lastname: Bonner
authors.forename: Thomas
authors.initials: T
authors.lastname: Matte
authors.forename: Mitchell
authors.initials: M
authors.lastname: Rubin
authors.forename: Joanne K
authors.initials: JK
authors.lastname: Fagan
authors.forename: Jennifer
authors.initials: J
authors.lastname: Ahern
authors.forename: David
authors.initials: D
authors.lastname: Evans
mesh_terms: D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001741:Black or African American / Q000706:statistics & numerical data; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000208:ethnology; D002673:Child, Hospitalized; D002675:Child, Preschool; D004205:Cromolyn Sodium / Q000008:administration & dosage / Q000627:therapeutic use; D003695:Delivery of Health Care / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006630:Hispanic or Latino / Q000706:statistics & numerical data; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D009519:New York City; D012138:Respiratory Therapy; D011795:Surveys and Questionnaires; D014504:Urban Health / Q000706:statistics & numerical data
chemical_list: D000305:Adrenal Cortex Hormones; D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D020024:Leukotriene Antagonists; D004205:Cromolyn Sodium